Aim:

To evaluate the antiproliferative activity of contragestazol (DL111-IT) on the human prostate cancer cell line PC3 in vitro and in vivo and to elucidate its potential molecular mechanisms.

Methods:

The cell killing ability of DL111-IT was measured by the 3-(4,5-dimethylthia-zol,2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent assay method and the tumor xenograft model. The cell cycle was analyzed by flow cytometry and protein expression, including retinoblastoma (pRb), cyclin-dependent kinase 4 (CDK4) and cyclin D1, was detected by Western blotting.

Results:

DL111-IT exhibited high efficiency on cell growth inhibition of the human androgen-independent prostate cancer cell line PC3. The drug concentration that yielded 50 % cell inhibition (IC50 value) was 9.9 mg/mL. In the PC3 tumor xenograft study, DL111-IT (1.25 mg/kg-20.0 mg/kg) given once a day for 10 days significantly inhibited tumor growth, with the inhibition rate ranging from 21 % to 50 %. Flow cytometric analysis indicated that DL111-IT could cause G1 arrest in the PC3 cell line, but not apoptosis. DL111-IT enhanced pRb expression and down-regulated CDK4 and cyclin D1 expression, suggesting that cell cycle regulation might contribute to the anticancer property of DL111-IT.

Conclusion:

DL111-IT inhibits the proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo by a cell cycle regulation pathway.

References

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999; 49: 8–31. | Article | PubMed | ISI | ChemPort |
2. Vercelli M, Quaglia A, Marani E, Parodi S. Prostate cancer incidence and mortality trends among elderly and adult Europeans. Crit Rev Oncol Hematol 2000; 35: 133–44. | Article | PubMed | ChemPort |
3. Gao HW, Li YL, Wu S, Wang YS, Zhang HF, Pan YZ, et al. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J Androl 2005 Jun; 7: 159–63. | Article | PubMed | ISI |
4. Galliani G, Luzzani F, Colombo G, Conz A, Mistrello L, Baroae D, et al. On the mode of action of a new contragestational agent (DL111–IT). Contraception 1986; 33: 263–83. | Article | PubMed | ChemPort |
5. Yang B, Fang RY. Synergistic effects on pregnancy-termination activity of DL111–IT in combination with mifepristone. Acta Pharmacol Sin 1996; 17: 361–5. | ChemPort |
6. He QJ, Yang B, Wang WF, Wu HH, Fang RY. Synergistic effects of DL111–IT in combination with mifepristone and misoprostol on termination of early pregnancy in preclinical studies. Contraception 2003; 68: 289–95. | Article | PubMed | ChemPort |
7. Yang B, Cao L, Fang RY, Gu ZP. Luteolytic effects of DL111–IT in pregnant rats. Eur J Pharmacol 1999; 380: 145–52. | Article | PubMed |
8. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 1998; 35: 95–101. | Article | PubMed | ISI | ChemPort |
9. Wang L, Liu D, Ahmed T, Chung FL, Conaway C, Chiao JW. Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. Int J Oncol 2004; 24: 187–92. | PubMed |
10. Cao MY, Lee Y, Feng NP, Al-Qawasmeh RA, Viau S, Gu XP, et al. NC381, a novel anticancer agent, arrests the cell cycle in G0–G1 and inhibits lung tumor cell growth in vitro and in vivo. J Pharmacol Exp Ther 2004; 308: 538–46. | Article | PubMed | ChemPort |
11. Maddison LA, Sutherland DW, Darrios RJ, Greenberg NM. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res 2004; 64: 6018–25. | Article | PubMed | ISI | ChemPort |
12. Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 1998; 16: 1913–20. | Article | PubMed | ISI | ChemPort |